PubRank

Gerardo Guillén

Author PubWeight™ 36.47‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 2006 1.24
2 Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 2010 1.10
3 Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin Vaccine Immunol 2007 0.97
4 Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res 2006 0.94
5 A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 2009 0.93
6 Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch Virol 2008 0.93
7 The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol 2009 0.88
8 A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods 2004 0.87
9 Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg 2003 0.87
10 Viremia and the magnitude of the immune response upon infection of green monkeys with dengue virus type 2 are strain-dependent. Curr Microbiol 2009 0.86
11 Viremia and antibody response in green monkeys (Chlorocebus aethiops sabaeus) infected with dengue virus type 2: a potential model for vaccine testing. Microbiol Immunol 2009 0.85
12 Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine 2008 0.85
13 Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. Int Wound J 2006 0.85
14 A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol Appl Biochem 2004 0.83
15 The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2. Clin Vaccine Immunol 2011 0.83
16 Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clin Sci (Lond) 2007 0.82
17 Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes. Clin Vaccine Immunol 2009 0.82
18 Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. Int J Infect Dis 2009 0.82
19 Ubiquitous expression of human SCA2 gene under the regulation of the SCA2 self promoter cause specific Purkinje cell degeneration in transgenic mice. Neurosci Lett 2005 0.82
20 A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine 2006 0.81
21 Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res 2008 0.81
22 The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice. Vaccine 2011 0.80
23 Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine 2005 0.80
24 In vitro assembly of nucleocapsid-like particles from purified recombinant capsid protein of dengue-2 virus. Arch Virol 2009 0.80
25 Enzyme-linked immunosorbent assay for quantitative determination of capsular polysaccharide production in Streptococcus pneumoniae clinical isolates. Biotechnol Appl Biochem 2006 0.80
26 Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. Int Immunol 2009 0.80
27 Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus. Arch Virol 2012 0.79
28 Identification and characterization of phage-displayed peptide mimetics of Neisseria meningitidis serogroup B capsular polysaccharide. Int J Med Microbiol 2010 0.78
29 The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs. Biochem Biophys Res Commun 2003 0.78
30 Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2006 0.78
31 Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64k protein conjugates. FEMS Immunol Med Microbiol 2004 0.78
32 Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem 2009 0.77
33 Expression in Pichia pastoris and immunological evaluation of a truncated Dengue envelope protein. Mol Biotechnol 2007 0.77
34 Olive baboons: a non-human primate model for testing dengue virus type 2 replication. Int J Infect Dis 2013 0.77
35 Study of various presentation forms for a peptide mimetic of Neisseria meningitidis serogroup B capsular polysaccharide. Bioconjug Chem 2010 0.77
36 Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice. J Gen Virol 2012 0.77
37 A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice. Arch Virol 2014 0.77
38 Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus. Microbiol Immunol 2014 0.77
39 Proteomic study via a non-gel based approach of meningococcal outer membrane vesicle vaccine obtained from strain CU385: a road map for discovering new antigens. Hum Vaccin 2009 0.76
40 Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus. Arch Virol 2014 0.76
41 Comparison of three ELISA protocols to measure antibody responses elicited against serogroup C meningococcal polysaccharide in mouse, monkey and human sera. J Microbiol Methods 2005 0.76
42 Influence of aluminum-based adjuvant on the immune response to multiantigenic formulation. Viral Immunol 2006 0.76
43 Purified capsular polysaccharide of Neisseria meningitidis serogroup A as immune potentiator for antibody production. Curr Microbiol 2009 0.76
44 A vaccine formulation consisting of nucleocapsid-like particles from Dengue-2 and the fusion protein P64k-domain III from Dengue-1 induces a protective immune response against the homologous serotypes in mice. Acta Trop 2012 0.75
45 Safety and preliminary immunogenicity of MenC/P64k, a meningococcal serogroup C conjugate vaccine with a new recombinant carrier. FEMS Immunol Med Microbiol 2006 0.75
46 Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci 2012 0.75
47 Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2. Antiviral Res 2012 0.75
48 Immunologic memory response induced by a meningococcal serogroup C conjugate vaccine using the P64k recombinant protein as carrier. FEMS Immunol Med Microbiol 2006 0.75
49 Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus. Arch Virol 2010 0.75
50 Gonadotrophin releasing hormone-based vaccine, an effective candidate for prostate cancer and other hormone-sensitive neoplasms. Adv Exp Med Biol 2008 0.75
51 The serogroup A capsular polysaccharide from Neisseria meningitidis enhances the cell-mediated immunity and the protective capacity induced by a dengue fusion protein in mice. Arch Virol 2012 0.75